Latest news with #USPatentandTrademarkOffice
Yahoo
29-05-2025
- Business
- Yahoo
BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors
On Wednesday, BioAffinity Technologies Inc. (NASDAQ:BIAF) announced that the US Patent and Trademark Office/USPTO has issued a new patent. The patent is titled "Compositions and Methods for Treating Cancer," and covers a novel method and composition for selectively eliminating cancer cells by targeting the CD320 and LRP2 receptors on the cell membrane. The therapeutic approach outlined in the patent applies to a broad spectrum of cancers, including those of the lung, breast, prostate, brain, and skin. BioAffinity Technologies has already initiated research towards developing a topical treatment for skin cancers. The new patent supports the company's intellectual property portfolio, which now includes 19 awarded US and foreign patents and 36 pending patent applications related to its diagnostic platform and cancer treatment therapeutics. A medical professional in a hospital, using targeted cancer therapuetics to treat cancer patients. The invention utilizes small interfering RNAs (siRNAs) to suppress the expression of CD320 and LRP2 proteins. In vitro studies have demonstrated that the simultaneous knockdown of both proteins is selectively cytotoxic to human cancer cells, while sparing normal cells under the same treatment conditions. The studies also indicated that the double knockdown of CD320 and LRP2 is crucial, as down-regulating only one receptor led to increased protein expression in the other, and was insufficient to kill cancer cells or significantly inhibit their proliferation. BioAffinity Technologies Inc. (NASDAQ:BIAF) develops non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the US. It operates through two segments: Diagnostic R&D and Laboratory Services. While we acknowledge the potential of BIAF to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIAF and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors
On Wednesday, BioAffinity Technologies Inc. (NASDAQ:BIAF) announced that the US Patent and Trademark Office/USPTO has issued a new patent. The patent is titled "Compositions and Methods for Treating Cancer," and covers a novel method and composition for selectively eliminating cancer cells by targeting the CD320 and LRP2 receptors on the cell membrane. The therapeutic approach outlined in the patent applies to a broad spectrum of cancers, including those of the lung, breast, prostate, brain, and skin. BioAffinity Technologies has already initiated research towards developing a topical treatment for skin cancers. The new patent supports the company's intellectual property portfolio, which now includes 19 awarded US and foreign patents and 36 pending patent applications related to its diagnostic platform and cancer treatment therapeutics. A medical professional in a hospital, using targeted cancer therapuetics to treat cancer patients. The invention utilizes small interfering RNAs (siRNAs) to suppress the expression of CD320 and LRP2 proteins. In vitro studies have demonstrated that the simultaneous knockdown of both proteins is selectively cytotoxic to human cancer cells, while sparing normal cells under the same treatment conditions. The studies also indicated that the double knockdown of CD320 and LRP2 is crucial, as down-regulating only one receptor led to increased protein expression in the other, and was insufficient to kill cancer cells or significantly inhibit their proliferation. BioAffinity Technologies Inc. (NASDAQ:BIAF) develops non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the US. It operates through two segments: Diagnostic R&D and Laboratory Services. While we acknowledge the potential of BIAF to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIAF and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Morocco World
13-05-2025
- Automotive
- Morocco World
Moroccan Rachid Yazami Secures New USPTO Patent for EV Battery Security Tech
Rabat — Moroccan scientist Rachid Yazami has secured a new patent from the US Patent and Trademark Office (USPTO) for a groundbreaking method to detect early internal short-circuit signs in batteries. The method helps detect the hazardous process of thermal runaway, one of the primary causes that can lead to dangerous fires or explosions, particularly in electric vehicles (EVs). Yazami took to his social media to break the news and share the descriptive patent that portrays the system's approach, which is based on real-time analysis of thermodynamic and kinetic data emanating from an electrochemical cell. The renowned Moroccan scientist said that his team is delighted and that this invention 'relates to the premature detection of an internal short circuit in a battery, which is the main cause of thermal runaway (fire, explosion, etc.).' Yazami further expressed hopes that this new invention will contribute to saving lives from one of the most serious risks associated with batteries. The system measures parameters such as open-circuit voltage, entropy, and enthalpy variations, thus identifying early signs of an internal short-circuit. This would contribute to preventive intervention before thermal runaways happen and lead to fire or explosions. In the context of growing adoption of electrification in transport, the patent represents a significant contribution to battery safety in EVs. Speaking to Morocco World News (MWN) on the sidelines of the Global Industry 4.0 2023 event in Casablanca, the scientist expressed the need for batteries to be tailored according to the market's unique environmental conditions, where temperatures can reach over 50 degrees Celsius. This breakthrough reflects Yazami's ongoing commitment to improving the reliability and safety of energy storage systems. The patent was originally filed on May 28, 2019. Read also: Moroccan Scientist Rachid Yazami Wins 2023 VinFuture Grand Prize In January, he received his second patent from China for the same safety feature that aims to reduce the risk of EV's batteries catching fire or exploding. He also received his first patent for the original EV battery fast-charging technology from both China and Japan. Yazami's inventions focus mainly on facilitating fast-charging technologies for lithium batteries used in both electronic devices and electric vehicles. These breakthroughs are in line with Morocco's strategy to shift to greener energy solutions, adopting renewable energy strategies that would contribute to the world's fight against climate change.
Time of India
08-05-2025
- Automotive
- Time of India
Tesla's 'Robotaxi' trademark refused for being too generic: Report
The US Patent and Trademark Office has refused Tesla 's attempt to trademark the term "Robotaxi" in reference to its vehicles, TechCrunch reported on Wednesday, citing a filing. Another application by Tesla to trademark the term "Robotaxi" for its upcoming ride-hailing service is still under examination by the office, the report said. The USPTO issued on Tuesday a "nonfinal office action" on the Robotaxi trademark application, which means Tesla has three months to file a response or the office will abandon the application, the report added. Applications from Tesla for the trademark on the term "Cybercab" have been halted due to other companies pursuing similar "Cyber" trademarks, according to TechCrunch. Tesla did not immediately respond to a Reuters request for comment. Last month, Tesla said its plan to roll out " autonomous ride-hailing for money" by June in Austin , Texas , remained on track. The EV maker said in April it would have to reassess its growth forecast in three months because it was "difficult to measure the impacts of shifting global trade policy on the automotive and energy supply chains." The "changing political sentiment could have a meaningful impact on demand for our products in the near-term," it said.
Economic Times
08-05-2025
- Automotive
- Economic Times
Tesla's 'Robotaxi' trademark refused for being too generic: Report
Live Events The US Patent and Trademark Office has refused Tesla 's attempt to trademark the term "Robotaxi" in reference to its vehicles, TechCrunch reported on Wednesday, citing a application by Tesla to trademark the term "Robotaxi" for its upcoming ride-hailing service is still under examination by the office, the report USPTO issued on Tuesday a "nonfinal office action" on the Robotaxi trademark application, which means Tesla has three months to file a response or the office will abandon the application, the report from Tesla for the trademark on the term "Cybercab" have been halted due to other companies pursuing similar "Cyber" trademarks, according to did not immediately respond to a Reuters request for month, Tesla said its plan to roll out " autonomous ride-hailing for money" by June in Austin Texas , remained on EV maker said in April it would have to reassess its growth forecast in three months because it was "difficult to measure the impacts of shifting global trade policy on the automotive and energy supply chains."The "changing political sentiment could have a meaningful impact on demand for our products in the near-term," it said.
